Global Extracellular Vesicles Based Liquid Biopsy Market, By Offering (Kits and Assays, Services, Instruments), Technology (Isolation, Analysis), Workflow (Sample Preparation, Sequencing, Data Analysis), End User (Academic and Research Institutes, Clinical Laboratories, Pharmaceutical and Biotechnology Companies) – Industry Trends and Forecast to 2031.
Extracellular Vesicles Based Liquid Biopsy Market Analysis and Size
The extracellular vesicles (EVs) based liquid biopsy market is experiencing robust growth, driven by a rising demand for non-invasive diagnostic methods and advancements in liquid biopsy technologies. Extracellular vesicles, including exosomes and microvesicles, have gained prominence as valuable sources of biomarkers for various diseases, such as cancer and neurodegenerative disorders. The market is witnessing increased research and development activities, collaborations, and strategic partnerships among key industry players, fostering innovation in EV-based liquid biopsy solutions. The expanding prevalence of cancer, coupled with a growing awareness of the potential of liquid biopsy in early detection and monitoring of diseases, is further propelling market growth.
Data Bridge Market Research analyzes that the global extracellular vesicles based liquid biopsy market which was USD 94.88 million in 2023, is likely to reach up to USD 444.70 million by 2031, and is expected to undergo a CAGR of 21.3% during the forecast period. “Kits and assays” dominates the offering segment of the market due to the increasing adoption of isolation kits, assays, and accessories. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Offering (Kits and Assays, Services, Instruments), Technology (Isolation, Analysis), Workflow (Sample Preparation, Sequencing, Data Analysis), End User (Academic and Research Institutes, Clinical Laboratories, Pharmaceutical and Biotechnology Companies)
|
|
Countries Covered
|
U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of Asia-Pacific, South Africa, Rest of Middle East and Africa, Brazil, Rest of South America
|
|
Market Players Covered
|
Bio-Techne Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Exosome Diagnostics, Inc. (U.S.), Aethlon Medical, Inc. (U.S.), System Biosciences, LLC (U.S.), NanoSomix, Inc. (U.S.), Malvern Panalytical Ltd. (U.K.), Norgen Biotek Corp. (Canada), Hitachi Chemical Co., Ltd. (Japan), Lonza Group Ltd. (Switzerland), Codiak BioSciences, Inc. (U.S.), NX Pharmagen (South Korea), Stemcell Technologies Inc. (Canada), Aruna Bio (U.S.), Evomic Science LLC (U.S.), Izon Science Ltd. (New Zealand), Exovita Biosciences (U.S.), Anergis SA (Switzerland), System Biosciences (SBI) (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Extracellular Vesicles (EVs) Based Liquid Biopsy is a cutting-edge diagnostic approach that involves the isolation and analysis of extracellular vesicles, such as exosomes and microvesicles, from biofluids like blood, urine, or cerebrospinal fluid. These vesicles, released by cells into the extracellular environment, contain a diverse cargo of proteins, nucleic acids, and lipids reflective of their cell of origin. Utilizing liquid biopsy techniques, EVs are extracted non-invasively, offering a valuable source of biomarkers for various diseases, particularly cancer. The analysis of EV content provides insights into the molecular and genetic signatures of pathological conditions, enabling early detection, monitoring of disease progression, and assessment of treatment response.
Global Extracellular Vesicles Based Liquid Biopsy Market Dynamics
Drivers
- Growing Demand for Non-Invasive Nature of Liquid Biopsy
The non-invasive nature of extracellular vesicles (EVs) based liquid biopsy is a significant driver for market growth. Unlike traditional tissue biopsies, liquid biopsies, which utilize EVs from biofluids like blood or urine, offer a less invasive and more patient-friendly approach for the diagnosis and monitoring of diseases. This characteristic is particularly appealing for individuals who may be averse to or ineligible for surgical procedures.
- Advancements in Liquid Biopsy Technologies
Ongoing advancements in liquid biopsy technologies, including improved isolation and characterization techniques for extracellular vesicles, are driving the growth of the market. Technological innovations contribute to enhanced sensitivity and specificity in detecting disease-associated biomarkers within EVs, making these liquid biopsy methods increasingly reliable and applicable for a broader range of diseases, including cancer and neurodegenerative disorders.
- Rising Prevalence of Cancer
The increasing prevalence of cancer globally is a major driver for the adoption of extracellular vesicles based liquid biopsy. As liquid biopsies, including EV-based approaches, become instrumental in the early detection and monitoring of cancer, the growing incidence of the disease fuels the demand for more effective and less invasive diagnostic methods, supporting the expansion of the market.
- Growing Investment for Healthcare Facilities
Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.
Opportunities
- Growing Emphasis on Personalized Medicine
The global shift toward personalized medicine and targeted therapies is boosting the demand for precise and molecularly-informed diagnostic tools. Extracellular vesicles based liquid biopsy provides a means to capture the dynamic molecular profile of diseases, supporting the trend toward personalized healthcare strategies. The ability to tailor treatments based on the specific genetic and molecular characteristics of each patient contributes to the market's growth as a crucial component of the evolving healthcare landscape.
- Expanded application in various diseases
The extracellular vesicles (EVs) based liquid biopsy market has the opportunity to expand its application beyond cancer to a broader spectrum of diseases. As research progresses, there is potential to identify and validate EV biomarkers for neurodegenerative disorders, cardiovascular diseases, and other conditions. Diversifying the application of EV-based liquid biopsy could significantly broaden the market's reach and impact on diagnostics and personalized medicine.
Restraints
- Standardization and lack of consensus
A major restraint in the extracellular vesicles (EVs) based liquid biopsy market is the lack of standardized isolation and analysis protocols. Variability in methodologies and a lack of consensus on best practices can lead to inconsistent results and hinder the widespread adoption of EV-based liquid biopsy. Establishing standardized procedures is crucial for ensuring the reliability and reproducibility of results across different laboratories and settings.
- Regulatory challenges and approval processes
The regulatory landscape for liquid biopsy technologies, including those based on extracellular vesicles, is evolving. Regulatory approval processes may vary across regions, and achieving standardized guidelines can be challenging. Stringent regulatory requirements and a lack of clear pathways for approval may slow down the commercialization and widespread adoption of EV-based liquid biopsy methods.
Challenges
- Ethical and privacy concerns
The use of liquid biopsy technologies, including those based on extracellular vesicles, raises ethical and privacy concerns. Issues related to the ownership of biological samples, informed consent, and the secure handling of sensitive patient data must be addressed. Ensuring compliance with ethical standards and regulatory frameworks, particularly as these technologies become more widespread, is essential for building trust among patients and stakeholders in the global healthcare community.
- Sample standardization and quality control
Ensuring consistent and standardized collection, processing, and storage of biofluid samples for extracellular vesicles (EVs) based liquid biopsy poses a significant challenge. Variability in sample handling can introduce biases and impact the reproducibility and reliability of results. Establishing standardized protocols for sample preparation and implementing stringent quality control measures are crucial for overcoming this challenge.
This extracellular vesicles based liquid biopsy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the extracellular vesicles based liquid biopsy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In January 2022, QIAGEN announced its new Biotech Grants program winners, an initiative driven by the company's commitment to building strong partnerships with biotechnology and pharma businesses and helping them succeed in the market. This has helped the company in revenue growth
- In January 2022, Exact Sciences Corporation announced the acquisition of Prevention Genetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT)
Global Extracellular Vesicles Based Liquid Biopsy Market Scope
The extracellular vesicles based liquid biopsy market is segmented on the basis of offering, technology, workflow and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Offering
- Kits and Assays
- Services
- Instruments
Technology
- Isolation
- Analysis
Workflow
- Sample Preparation
- Sequencing
- Data Analysis
End user
- Academic and Research Institutes
- Clinical Laboratories
- Pharmaceutical and Biotechnology Companies
Global Extracellular Vesicles Based Liquid Biopsy Market Regional Analysis/Insights
The extracellular vesicles based liquid biopsy market is analyzed and market size insights and trends are provided by country, offering, technology, workflow and end user as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Brazil, Argentina, the rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, and rest of the Middle East and Africa.
North America is expected to dominate the market due to the rise of large medical device manufacturers, the presence of major market players and increased technological advancement in the region.
Asia-Pacific is expected to observe significant amount of growth in the market due to the rapid necessity for telemedicine and healthcare support. Moreover, the modernization and development in telecommunication are further anticipated to propel the growth of the extracellular vesicles based liquid biopsy market in the region in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The extracellular vesicles based liquid biopsy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for extracellular vesicles based liquid biopsy market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the extracellular vesicles based liquid biopsy market. The data is available for historic period 2010-2020.
Competitive Landscape and Extracellular vesicles based liquid biopsy Market Share Analysis
The extracellular vesicles based liquid biopsy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to extracellular vesicles based liquid biopsy market.
Some of the major players operating in the extracellular vesicles based liquid biopsy market are:
- Bio-Techne Corporation (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- QIAGEN N.V. (Netherlands)
- Exosome Diagnostics, Inc. (U.S.)
- Aethlon Medical, Inc. (U.S.)
- System Biosciences, LLC (U.S.)
- NanoSomix, Inc. (U.S.)
- Malvern Panalytical Ltd. (U.K.)
- Norgen Biotek Corp. (Canada)
- Hitachi Chemical Co., Ltd. (Japan)
- Lonza Group Ltd. (Switzerland)
- Codiak BioSciences, Inc. (U.S.)
- NX Pharmagen (South Korea)
- Stemcell Technologies Inc. (Canada)
- Aruna Bio (U.S.)
- Evomic Science LLC (U.S.)
- Izon Science Ltd. (New Zealand)
- Exovita Biosciences (U.S.)
- Anergis SA (Switzerland)
- System Biosciences (SBI) (U.S.)
SKU-